SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris announced the publication of positive Phase 2 data from its…

Pharvaris N.V. · PRESS-RELEASE filed Mar 20, 2026 at 06:50 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 20, 2026 at 06:50 ET

Pharvaris announced the publication of positive Phase 2 data from its CHAPTER-1 and RAPIDe-1 trials in The Lancet Haematology, showing deucrictibant's efficacy and safety as both a prophylactic and on-demand oral treatment for hereditary angioedema (HAE). The results support its potential as a first-in-class oral B2 receptor antagonist for end-to-end HAE management, with Phase 3 topline data expected in Q3 2026.

  • Phase 2 CHAPTER-1 trial showed statistically significant reduction in HAE attack frequency with deucrictibant for prophylaxis.
  • Phase 2 RAPIDe-1 trial demonstrated statistically significant reduction in attack severity and faster symptom relief for on-demand treatment.
  • Deucrictibant is an oral bradykinin B2 receptor antagonist, positioning it as a potential first-in-class oral therapy for both prevention and acute treatment of HAE.
  • Topline data from pivotal Phase 3 RAPIDe-3 trial already confirmed faster symptom relief and single-capsule resolution in most attacks.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access